AJP - Regu Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 270: R660-R666, 1996;
0363-6119/96 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotchen, T. A.
Right arrow Articles by Hoffmann, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotchen, T. A.
Right arrow Articles by Hoffmann, R. G.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 270, Issue 3 660-R666, Copyright © 1996 by American Physiological Society

ARTICLES

Effect of pioglitazone on vascular reactivity in vivo and in vitro

T. A. Kotchen, H. Y. Zhang, S. Reddy and R. G. Hoffmann
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.

Pioglitazone (a thiazolidinedione derivative) increases insulin sensitivity and prevents hypertension in the Dahl-salt-sensitive (S) rat. The present study was undertaken to determine if pioglitazone modulates pressor responsiveness to vasoactive agents, both in vivo and in vitro. In vivo, pretreatment with pioglitazone inhibited (P < 0.02) pressor responses to both norepinephrine and angiotensin II in conscious Dahl-S, but not in Sprague-Dawley rats. In vitro, pioglitazone augmented the capacity of insulin to inhibit pressor responses of strips of thoracic aortas to norepinephrine, but not to angiotensin. Additionally, in vitro, incubation with insulin plus pioglitazone augmented acetylcholine-induced, but not nitroprusside-induced vasodilation. Pioglitazone pretreatment increased (P < 0.001) in vitro insulin-stimulated glucose uptake in adipose tissue, but not in thoracic aortas of Dahl-S. We hypothesize that pioglitazone attenuates hypertension by modulating the effects of insulin on vascular function, resulting in both blunted vasoconstriction and augmented acetylcholine-induced vasodilation. These alterations are not accounted for by an effect of pioglitazone on glucose uptake by vascular smooth muscle.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Zanchi, C. Perregaux, M. Maillard, D. Cefai, J. Nussberger, and M. Burnier
The PPAR{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1228 - E1234.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Arima, K. Kohagura, K. Takeuchi, Y. Taniyama, A. Sugawara, Y. Ikeda, M. Abe, K. Omata, and S. Ito
Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 342 - 349.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
T. A. Kotchen
Attenuation of Hypertension by Insulin-Sensitizing Agents
Hypertension, August 1, 1996; 28(2): 219 - 223.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online